Cranberry

Cranberry (Vaccinium macrocarpon) is the American large-fruited cranberry, a low evergreen shrub of the heath family (Ericaceae), native to the cool bogs of north-eastern North America and now commercially cultivated for its bright red, tart berries. The berry, the unsweetened juice, and standardised proanthocyanidin extracts in capsule form are the common product categories. In Austria the closer cultural and botanical reference point is Preiselbeere (Vaccinium vitis-idaea, lingonberry), a smaller European relative. American cranberry is an import product, more often encountered as juice or capsule than as fresh fruit.

The active compounds most often discussed are type-A proanthocyanidins (A-PACs), which give the berry its astringency and have been studied for an anti-adhesion effect on uropathogenic Escherichia coli in laboratory work. The European Medicines Agency (EMA HMPCEuropean Medicines Agency, Committee on Herbal Medicinal Products (HMPC)) has not issued a Community herbal monograph for cranberry (the category sits closer to food than to medicinal product in the European framework), and the European Food Safety Authority (EFSA) has rejected several Article 13.5 health-claim applications for cranberry on urinary tract function. We frame cranberry honestly as a traditional food and supplement with an evolving evidence base for women with recurrent urinary tract infections, not as a treatment for any condition.

Cranberry has a long history of food and medicinal use among the Native American peoples of the north-eastern woodlands, where the fresh berries were eaten, dried into pemmican with venison and fat for winter food, and used as a dye. The documented Indigenous medicinal record is narrow: the Montagnais used a branch infusion for pleurisy (Speck 1917). The use of cranberry as a poultice on inflammatory swellings such as erysipelas is a nineteenth-century domestic and Eclectic record (King's American Dispensatory, 1898), not a pre-contact Indigenous use. The English colonists of seventeenth-century New England learned the berry from the local people and gave it its modern English name; it became a staple of the Thanksgiving table and a commercial crop on Cape Cod and in Wisconsin by the nineteenth century. The Latin name macrocarpon (large-fruited) distinguishes it from the smaller European Vaccinium oxycoccos.

Modern Western interest in cranberry for urinary tract health dates roughly to mid-twentieth-century clinical observations and accelerated in the 1990s, when laboratory work identified the anti-adhesion effect of proanthocyanidins on uropathogenic E. coli. The Cochrane Collaboration has reviewed the evidence repeatedly. The 2012 update (Jepson and colleagues) found that the early enthusiasm was not supported by larger trials and that the benefit, if real, was small and weakened over time. Later Cochrane updates including the 2023 review have been somewhat more positive specifically for women with recurrent urinary tract infections, while remaining cautious about the size and quality of the evidence. EFSA has separately rejected multiple Article 13.5 health-claim applications for cranberry on urinary tract function, meaning no permitted EU health claim exists for this use.

The pharmacological story of cranberry centres on type-A proanthocyanidins (A-PACs), a class of condensed tannins concentrated in the berry skin. Type-A linkages are uncommon in the polyphenol world and give the cranberry PACs a particular three-dimensional shape. In laboratory work, type-A PACs interfere with the ability of uropathogenic E. coli to adhere to the urothelial cells lining the bladder. The bacteria use surface fimbriae to grip the urothelium; the PACs are thought to disrupt this grip. This is the anti-adhesion mechanism that anchors the traditional and modern interest in cranberry for urinary tract health.

Beyond the type-A PACs, cranberry carries organic acids (quinic, malic, citric, and benzoic acid, the last contributing to the characteristic shelf stability of fresh berries), anthocyanins responsible for the red colour, and a modest amount of vitamin C. The translation from the elegant in-vitro anti-adhesion mechanism to a meaningful clinical effect has not been straightforward; doses, product types, populations, and outcome definitions vary widely across the trials, and the EFSA reviewers have judged the overall evidence insufficient for a permitted health claim. The mechanism is real and well described; the clinical translation is partial.

The modern clinical evidence base for cranberry has evolved over thirty years. Jepson and colleagues published the 2012 Cochrane review, which pulled together the available randomised trials and concluded that the previously assumed benefit for urinary tract infection prevention had weakened with more and larger studies. Later Cochrane updates, including the 2023 review, have re-examined the evidence with a focus on specific populations and reported a modest benefit for women with recurrent urinary tract infections, with smaller or no benefit in other groups (older people in care settings, children, post-surgical or post-catheter populations). The body of work also documents wide variability in product type (juice, capsule, syrup, fresh berry), proanthocyanidin content, and the dose ranges actually tested.

The European regulatory picture is clear. EFSA has rejected multiple Article 13.5 health-claim applications for cranberry on urinary tract function, so no permitted EU health claim exists. The standardisation of cranberry capsules around 36 mg of proanthocyanidins per dose is widely used in clinical trials but is itself contested, because different assay methods give different PAC numbers for the same product. Cranberry is best read as a traditional food and supplement with an evolving and partial evidence base in one specific population (women with recurrent urinary tract infections), and as a genuinely unproven option in most other use cases. It is not a substitute for medical care of an acute urinary tract infection.

Forms and preparation

For unsweetened cranberry juice, look for a product that lists cranberry as the only fruit and contains no added sugar; many supermarket cranberry juices are heavily sweetened cocktails, which dilutes the proanthocyanidin content and adds a lot of sugar. Drink about 250 millilitres twice a day if you are using juice as the form. Pure unsweetened cranberry juice is very tart; many people dilute it with water or mix it with a less acidic juice to make it drinkable. For dried cranberries, check the label, because most commercial dried cranberries are sweetened. Standardised cranberry capsules typically deliver around 200 to 500 milligrams of cranberry extract standardised to a defined proanthocyanidin content (often quoted as 36 milligrams of PACs per daily dose, though different assays return different numbers for the same product). Capsules are an easier daily form than juice because they avoid the tartness and the sugar question entirely. Follow the dose on the package. For fresh or frozen berries, half a cup a day cooked briefly with a little water and a touch of sweetener makes a traditional compote that pairs well with savoury foods.

Dosage

The dose ranges that have been studied in clinical trials are roughly 200 to 500 milligrams of standardised cranberry extract per day for capsule forms, or about 250 millilitres of pure unsweetened cranberry juice taken twice a day. These ranges come from a body of trials that vary widely in product type and proanthocyanidin content. There is no single agreed dose, and the EFSA-rejected health claims tried a range of dosing patterns without consistent effect. Use cranberry as a regular daily supplement, not as a single-event treatment. The proposed benefit in the Cochrane evidence base is for prevention of recurrence in women who already have a pattern of repeated urinary tract infections, not for treatment of an active infection. For an acute urinary tract infection, see your doctor. Cranberry is not a substitute for antibiotics. If you choose to try cranberry alongside any other treatment, talk to your doctor or pharmacist first, especially if you take warfarin.